Pregnane X receptor activation constrains mucosal NF-κB activity in active inflammatory bowel disease

PLoS One. 2019 Oct 3;14(10):e0221924. doi: 10.1371/journal.pone.0221924. eCollection 2019.

Abstract

Background: The Pregnane X Receptor (PXR) is a principal signal transducer in mucosal responses to xenobiotic stress. It is well-recognized that inflammatory bowel disease is accompanied by xenobiotic stress, but the importance of the PXR in limiting inflammatory responses in inflammatory bowel disease remains obscure at best.

Methods: We stimulate a total of 106 colonic biopsies from 19 Crohn's disease patients with active disease, 36 colonic biopsies from 8 control patients, colonic organoids and various cell culture models (either proficient or genetically deficient with respect to PXR) in vitro with the PXR ligand rifampicin or vehicle. Effects on NF-κB activity are assessed by measuring interleukin-8 (IL-8) and interleukin-1ß (IL-1ß) mRNA levels by qPCR and in cell culture models by NF-κB reporter-driven luciferase activity and Western blot for signal transduction elements.

Results: We observe a strict inverse correlation between colonic epithelial PXR levels and NF-κB target gene expression in colonic biopsies from Crohn's disease patients. PXR, activated by rifampicin, is rate-limiting for mucosal NF-κB activation in IBD. The correlation between colonic epithelial PXR levels and NF-κB target gene expression was also observed in intestinal organoids system. Furthermore, in preclinical in vitro models of intestinal inflammation, including intestinal organoids, genetic inactivation of PXR unleashes NF-κB-dependent signal transduction whereas conversely NF-κB signaling reduces levels of PXR expression.

Conclusions: Our data indicate that the PXR is a major and clinically relevant antagonist of NF-κB activity in the intestinal epithelial compartment during inflammatory bowel disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biopsy
  • Cell Line, Tumor
  • Cytokines / metabolism
  • Humans
  • Inflammatory Bowel Diseases / metabolism*
  • Inflammatory Bowel Diseases / pathology
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / metabolism*
  • Intestinal Mucosa / pathology
  • NF-kappa B / metabolism*
  • Pregnane X Receptor / metabolism*
  • Rifampin / pharmacology
  • Signal Transduction / drug effects

Substances

  • Cytokines
  • NF-kappa B
  • Pregnane X Receptor
  • Rifampin

Grants and funding

M.L. [201506100033] and S.C. [201606760056] are supported by a China Scholarship Council stipend (https://www.chinesescholarshipcouncil.com/), M.P. receives funding from the Dutch Society for the Replacement of Animal Testing and ZONMW (2016/22827/ZONMW) for the financial support of this work (www.zonmw.nl). The sponsors were not involved study design, data collection and analysis, decision to publish, or preparation of the manuscript.